Conexeu Sciences Inc.(CNXU)

Biotechnology · Reno, NV

$3.32+0.20 (+6.41%)

Delayed quote: Oct 6, 2026, 9:39 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T13:41:49.240Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:41:49.240Z.

Quote observation: 2026-10-06T13:39:47.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 88,837,649
Total debt: N/A
Cash: N/A
TTM revenue: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CNXU EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

CNXU Competitors' EV/Sales Ratio

CNXU

Conexeu Sciences Inc.

Current

Market Cap

$88.84M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Equillium, Inc.

vs CNXU

Market Cap

$89.78M

EV/Sales Ratio

N/A

TTM Avg

3.31x

3Y Avg

1.36x

5Y Avg

1.36x

CRDF

Cardiff Oncology, Inc.

vs CNXU

Market Cap

$88.63M

EV/Sales Ratio

157.27x

TTM Avg

202.08x

3Y Avg

199.51x

5Y Avg

216.66x

ICCC

ImmuCell Corporation

vs CNXU

Market Cap

$89.11M

EV/Sales Ratio

3.02x

TTM Avg

2.76x

3Y Avg

2.60x

5Y Avg

2.86x

CCLD

CareCloud, Inc.

vs CNXU

Market Cap

$87.11M

EV/Sales Ratio

0.99x

TTM Avg

1.01x

3Y Avg

0.60x

5Y Avg

0.55x

ACRV

Acrivon Therapeutics, Inc. Common Stock

vs CNXU

Market Cap

$85.60M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ECOR

electroCore, Inc.

vs CNXU

Market Cap

$91.96M

EV/Sales Ratio

2.52x

TTM Avg

1.93x

3Y Avg

2.28x

5Y Avg

2.11x

BMEA

Biomea Fusion, Inc.

vs CNXU

Market Cap

$91.82M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ATRA

Atara Biotherapeutics, Inc.

vs CNXU

Market Cap

$83.97M

EV/Sales Ratio

14.63x

TTM Avg

5.59x

3Y Avg

5.59x

5Y Avg

17.86x

HUMA

Humacyte, Inc.

vs CNXU

Market Cap

$84.52M

EV/Sales Ratio

33.38x

TTM Avg

52.52x

3Y Avg

427.47x

5Y Avg

706.12x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Conexeu Sciences Inc. (CNXU)	$88.84M	N/A	N/A	N/A	N/A
Equillium, Inc. (EQ)vs ›	$89.78M	N/A	3.31x	1.36x	1.36x
Cardiff Oncology, Inc. (CRDF)vs ›	$88.63M	157.27x	202.08x	199.51x	216.66x
ImmuCell Corporation (ICCC)vs ›	$89.11M	3.02x	2.76x	2.60x	2.86x
CareCloud, Inc. (CCLD)vs ›	$87.11M	0.99x	1.01x	0.60x	0.55x
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$85.60M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$91.96M	2.52x	1.93x	2.28x	2.11x
Biomea Fusion, Inc. (BMEA)vs ›	$91.82M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$83.97M	14.63x	5.59x	5.59x	17.86x
Humacyte, Inc. (HUMA)vs ›	$84.52M	33.38x	52.52x	427.47x	706.12x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics